Nyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical Technology
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced that Genio®, its hypoglossal nerve stimulation therapy for OSA, was awarded the Prix Galien UK 2026 Award for Best Medical Technology at a ceremony held in London.
The Prix Galien Award is widely regarded as one of the highest honors in healthcare innovation, recognizing technologies that deliver meaningful advances in patient care and outcomes. The award recognizes Genio’s contribution to the treatment of Obstructive Sleep Apnea, a chronic condition affecting millions of people and associated with increased risks of cardiovascular disease, metabolic disorders, impaired quality of life and excessive daytime sleepiness.
“What makes this recognition particularly special is that it reflects the efforts of so many people behind the scenes. From the engineers who developed the technology, to our UK team and staff supporting patients, to the physicians implanting the therapy and the patients who placed their trust in us, this achievement belongs to all of them,” said Olivier Taelman, Chief Executive Officer.
Nyxoah also wishes to acknowledge the clinicians, healthcare professionals and patients who have supported the development, evaluation and adoption of Genio around the world. In the United Kingdom, the award reflects the commitment of a growing team working alongside NHS and private healthcare partners to expand access to innovative treatment options for patients living with Obstructive Sleep Apnea.
The award comes during a period of significant momentum for Nyxoah. Following FDA approval and the commercial launch of Genio in the United States, the Company recently secured new financing to accelerate its U.S. expansion, while adoption of Genio continues to grow across Europe and other international markets.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
